Medication info
Romethan Tablet 5/40 mg

Romethan Tablet 5/40 mg

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›40mg / 1 tabletAmlodipine Besylate›6.944mg / 1 tablet
Manufacturer / importer
Genewon Science Co., Ltd.
Appearance
Pale yellow round film-coated tablets
Packaging
28 tablets/box [14 tablets/PTP×2]
Approval status
Active

MFDS item code 201405131 · Approved 2014.11.03 · Insurance code 671704380

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). It is recommended to adjust the dose using the individual components (amlodipine or olmesartan medoxomil) before administering this medicine; however, switching directly to this medicine may be considered if blood pressure is not controlled with monotherapy using the individual components. The maximum dose of this medicine is 10/40 mg. Since the maximum antihypertensive effect occurs within 2 weeks after administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ○Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and administration of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ○Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See Section 2. Patients Who Should Not Take This Medicine under Precautions for Use.) ○Older adults: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored more frequently and closely in older adults.
Child dose
○Children: The safety and efficacy in pediatric patients under 18 years of age have not been established.

Ingredients

Manufacturer
Genewon Science Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication is used for patients with essential hypertension who have difficulty controlling blood pressure with either amlodipine or olmesartan medoxomil monotherapy. It helps manage hypertension effectively, reducing cardiovascular risk and improving health.

How to take

Adult dose

Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). It is recommended to adjust the dose using the individual components (amlodipine or olmesartan medoxomil) before administering this medicine; however, switching directly to this medicine may be considered if blood pressure is not controlled with monotherapy using the individual components. The maximum dose of this medicine is 10/40 mg. Since the maximum antihypertensive effect occurs within 2 weeks after administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ○Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and administration of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ○Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See Section 2. Patients Who Should Not Take This Medicine under Precautions for Use.) ○Older adults: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored more frequently and closely in older adults.

Child dose

○Children: The safety and efficacy in pediatric patients under 18 years of age have not been established.

Precautions

This medication may cause serious harm to the fetus and newborn when taken during pregnancy in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. Patients with hypersensitivity to any component of this medication, pregnant or nursing women, patients with severe liver impairment or aortic stenosis, those with biliary obstruction, patients undergoing kidney dialysis, patients in shock, and specific diabetic patients should not take this medication. Patients with deficiency of water or salt may experience symptoms of low blood pressure at the beginning of treatment with this medication, so their condition should be monitored closely, and appropriate measures should be taken if hypotension occurs. This medication can cause vasodilation, and in rare cases, acute hypotension may occur; hence caution is needed, especially in patients with aortic stenosis. Patients with severe coronary artery obstruction should be cautious, as angina or myocardial infarction may worsen while taking this medication. Patients with heart failure should also be closely monitored while taking this medication, and those with reduced kidney function should be aware of changes in kidney function. Patients with reduced liver function should take this medication with caution. While taking this medication, side effects such as dizziness, headache, hypotension, orthostatic hypotension, edema, dyspepsia, rash, etc., may occur, so any unusual symptoms should be reported to a doctor immediately. Women who are pregnant or planning to become pregnant should be switched to other safe antihypertensive treatments instead of this medication, and it should be discontinued immediately upon confirmation of pregnancy. Nursing mothers should be aware that this medication may pass into breast milk, potentially causing side effects in infants, so breastfeeding or taking this medication should be discontinued. Children under 18 years of age should not take this medication as its safety and efficacy have not been established. Elderly patients should start with a low dose considering reduced liver, kidney, and heart function and other illnesses for safety. In case of overdose, severe hypotension and vascular dilation may occur, and immediate medical treatment is needed; blood pressure raising medications may be required if necessary. This medication should be stored in a tightly closed container to avoid exposure to moisture and heat, out of reach of children.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • paresthesia
  • hypoaesthesia
  • syncope
Show 84 more
  • vertigo
  • palpitations
  • tachycardia
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • dyspepsia
  • diarrhea
  • constipation
  • dry mouth
  • upper abdominal pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • back pain
  • pollakiuria
  • erectile dysfunction
  • peripheral edema
  • edema
  • pitting edema
  • fatigue
  • asthenia
  • facial edema
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • elevated gamma-glutamyl transferase
  • decreased hemoglobin and hematocrit
  • cholelithiasis
  • female breast neoplasm
  • exacerbation of cerebral infarction
  • gum bleeding
  • orthostatic dizziness
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • runny nose
  • laryngitis
  • arthritis
  • flank pain
  • generalized pain
  • hypoglycemia
  • weight loss
  • heartburn
  • gastroenteritis
  • herpes zoster
  • diplopia
  • insomnia
  • asthenia
  • vascular edema
  • chronic malabsorption syndrome
  • intestinal vascular edema
  • rhabdomyolysis
  • acute kidney failure
  • elevated serum creatinine
  • hair loss
  • itching
  • autoimmune hepatitis
  • vascular edema
  • flushing
  • fatigue
  • edema
  • palpitations
  • dizziness
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • hypotension
  • tachycardia
  • bradycardia
  • non-cardiogenic pulmonary edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent exposure to air or moisture. It is important to maintain a storage temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Pale yellow round film-coated tablets

Package unit

28 tablets/box [14 tablets/PTP×2]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.